UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1378-4
Program Prior Authorization/Notification
Medication Livtencity (maribavir)
P&T Approval Date 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Livtencity is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated in adults and
pediatric patients (12 years of age and older and weighing at least 35 kg) for the treatment of
post-transplant CMV infection/disease that is refractory to treatment (with or without
genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. Livtencity may
antagonize the antiviral activity of ganciclovir and valganciclovir and coadministration is not
recommended.
2. Coverage Criteriaa:
A. Authorization
1. Livtencity will be approved based on the following criterion:
a. Diagnosis of post-transplant cytomegalovirus (CMV) infection or CMV disease
-AND-
b. CMV infection or disease is refractory to treatment (with or without genotypic
resistance) to one of the following:
(1) Ganciclovir
(2) Valganciclovir
(3) Cidofovir
(4) Foscarnet
-AND-
c. Patient is not receiving Livtencity in combination with ganciclovir or
valganciclovir
Authorization will be issued for 2 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
4. References:
1. Livtencity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.;
March 2024.
Program Prior Authorization/Notification – Livtencity (maribavir)
Change Control
2/2022 New program.
2/2023 Annual review. Added state mandate and updated reference.
2/2024 Annual review. Updated background and reference.
2/2025 Annual review. Updated background and reference.
© 2025 UnitedHealthcare Services Inc.
2